Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

Glatt, Sophie; Jemec, Gregor B. E.; Forman, Seth; Sayed, Christopher; Schmieder, George J.; Weisman, Jamie; Rolleri, Robert; Seegobin, Seth; Baeten, Dominique; Ionescu, Lucian; Zouboulis, Christos C.; Shaw, Stevan

doi:10.1001/jamadermatol.2021.2905

Cited by 118 publications

(61 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 29 Moreover, bimekizumab had favorable effects on active psoriatic arthritis, 28 ankylosing spondylitis, 30 and hidradenitis suppurativa. 31 Overall, the results of this study on patients with moderate-to-severe psoriasis support the superior efficacy of bimekizumab.…”

Section: Discussionsupporting

confidence: 56%

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials

Wang

Bai

et al. 2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, and is a promising drug for patients with moderate-to-severe plaque psoriasis. Objectives: This study aimed to assess the efficacy and safety of bimekizumab in treating patients with psoriasis and to determine the optimal maintenance dosing schedules of bimekizumab. Methods and design: Eligible trials were identified from PubMed, Cochrane Controlled Register of Trials, Embase, ClinicalTrials.gov, and Chinese medical databases. Only double-blind, randomized, active comparator, or placebo-controlled trials of bimekizumab treatment on patients with psoriasis were included in this study. Results: Five studies were identified, which included 2473 patients with moderate-to-severe plaque psoriasis. The results indicated that bimekizumab had better efficacy than placebo or active comparator for Psoriasis Area and Severity Index (PASI) 90 [risk ratio (RR) = 29.29, 1.52; 95% confidence interval (CI) = 10.30–83.30, 1.06–2.19], PASI 100 (RR = 59.87, 2.06; 95% CI = 15.06–237.99, 1.12–3.79), and Investigator’s Global Assessment scores of 0 or 1 (IGA 0/1) (RR = 21.55, 1.36; 95% CI = 9.25–50.19, 1.02–1.81). Faster onset of clinically meaningful responses was observed with bimekizumab compared with both active comparators (RR = 2.59; 95% CI = 1.32–5.10) and placebo (RR = 40.46; 95% CI = 13.19–124.13), with PASI 75 response observed at week 4 after one dose. Subgroup analysis showed no significant difference in the reduction of PASI scores between 320 mg q4w dosage and q8w dosage (RR = 1.00; 95% CI = 0.96–1.03). Rates of patients with adverse events (AEs) were comparable in the bimekizumab and active comparator groups (RR = 1.13; 95% CI = 1.01–1.26), and oral candidiasis was one of the most common treatment-emergent AEs. Conclusion: The results of this meta-analysis suggest that bimekizumab is more efficacious and has a rapid onset of action than active comparators and placebo in the treatment of moderate-to-severe plaque psoriasis. After 16 weeks of initial maintenance treatment, both bimekizumab maintenance dosing schedules (320 mg every 4 and 8 weeks) had similar efficacy.

show abstract

Section: Discussionsupporting

confidence: 56%

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials

Wang

Bai

et al. 2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…Secukinumab (an anti-IL-17a monoclonal antibody) demonstrated superiority over placebo after 16 weeks of treatment in patients with moderate-to-severe HS in two recent phase III studies (SUNSHINE [ClinicalTrials.gov identifier NCT03713619] and SUNRISE [ClinicalTrials.gov identifier NCT03713632]) [22]. Clinically meaningful improvements have also been reported from open-label cohort studies for brodalumab (an IL-17a receptor antagonist) [23,24] and from phase II randomized controlled trials for HS with bimekizumab (an anti-IL-17a /IL-17F monoclonal antibody) [25] and povorcitinib (an oral, small-molecule Janus kinase 1 inhibitor) [26]. Clinical responses reported with anti-IL-17 agents, but not anti-IL-23 antibodies might suggest that IL-17-producing cells other than T helper 17 cells may be involved in the pathophysiology of HS.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

Kimball

Prens

Passeron

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life. This study evaluated the efficacy and safety of risankizumab, a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit, for the treatment of HS. Methods: This phase II multicenter, randomized, placebo-controlled, double-blind study investigated the efficacy and safety of risankizumab in patients with moderate-to-severe HS. Patients were randomized 1:1:1 to receive subcutaneous risankizumab 180 mg; risankizumab

show abstract

“…family has been widely involved in the HS inflammatory pathway [5,6]. According to clinical trials, HS improves on treatment with IL-17 antagonists [29,30]. The involved cytokines family in common could potentially explain the association between HS, atopic dermatitis and asthma.…”

Section: Discussionmentioning

confidence: 99%

Risk of Atopic Diseases in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Observational Studies

2023

View full text Add to dashboard Cite

Background Hidradenitis suppurativa (HS) and allergic diseases were considered to have different immune pathways involved. However, available evidences seemed to be inconsistent and the association was not well-developed yet. Objective To perform a systematic review and meta-analysis to evaluate the association between HS and atopic diseases, including asthma, atopic dermatitis, allergic rhinitis and conjunctivitis. Methods Search in databases including PubMed, Embase and Web of Science were performed. Synonyms were determined based on MeSH terms and Emtree. Observational studies with proper comparative arm were selected. For quality evaluation of extracted studies, the Newcastle-Ottawa Scale was utilized. Odds ratio of atopic dermatitis, asthma, allergic rhinitis and conjunctivitis were evaluated in HS patients (comparing with non-HS people). I2 value was applied to evaluate the heterogeneity within studies. Results After appraising 1,654 studies, in total, 12 studies were selected for data extraction. In adjusted models, people with HS is significantly associated with higher risk of having asthma, with a pooled odds ratio of 1.50 (95% CI, 1.24-1.81). Risk of presenting atopic dermatitis in HS patients was also increased, with an odd ratio of 4.10 (95% CI, 2.16-8.18). The association remained its significance in sensitivity models. Evidences were insufficient to support the association between HS and allergic rhinitis and conjunctivitis. Conclusion Current evidence supported that atopic dermatitis and asthma were associated with HS. Physicians should be aware of the reported association while caring people with HS and related screening of allergies comorbidities should be recommended.

show abstract

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

Cited by 118 publications

References 50 publications

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

Risk of Atopic Diseases in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Observational Studies

Contact Info

Product

Resources

About